Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Mallinckrodt
Dow
Boehringer Ingelheim
McKinsey

Last Updated: December 8, 2021

DrugPatentWatch Database Preview

Patent: 8,591,897

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,591,897
Title:Anti-ERBB2 antibody adjuvant therapy
Abstract: The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN.RTM..
Inventor(s): Bryant; John L. (Allison Road, PA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:11/400,638
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,591,897
Patent Claims:see list of patent claims

Details for Patent 8,591,897

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Free Forever Trial 2025-05-13
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Free Forever Trial 2025-05-13
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 2019-02-28 ⤷  Free Forever Trial 2025-05-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Moodys
Mallinckrodt
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.